Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast Cancer
Status: Enrolling
Updated:  3/21/2018
M D Anderson Cancer Center
mi
from
Houston, TX
Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast Cancer
Status: Enrolling
Updated: 3/21/2018
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast Cancer
Status: Enrolling
Updated:  3/21/2018
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast Cancer
Status: Enrolling
Updated: 3/21/2018
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
Abraxane and Trastuzumab Followed by Dose Dense Doxorubicin and Cyclophosphamide as Neoadjuvant Therapy in Invasive Breast Cancer With Low HER2 Expression (1+ or 2+ by IHC)
Status: Enrolling
Updated:  3/21/2018
Hays Medical Center
mi
from
Hays, KA
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
Abraxane and Trastuzumab Followed by Dose Dense Doxorubicin and Cyclophosphamide as Neoadjuvant Therapy in Invasive Breast Cancer With Low HER2 Expression (1+ or 2+ by IHC)
Status: Enrolling
Updated: 3/21/2018
Hays Medical Center
mi
from
Hays, KA
Click here to add this to my saved trials
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
Abraxane and Trastuzumab Followed by Dose Dense Doxorubicin and Cyclophosphamide as Neoadjuvant Therapy in Invasive Breast Cancer With Low HER2 Expression (1+ or 2+ by IHC)
Status: Enrolling
Updated:  3/21/2018
University of Kansas Medical Center Cancer Center
mi
from
Kansas City, KA
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
Abraxane and Trastuzumab Followed by Dose Dense Doxorubicin and Cyclophosphamide as Neoadjuvant Therapy in Invasive Breast Cancer With Low HER2 Expression (1+ or 2+ by IHC)
Status: Enrolling
Updated: 3/21/2018
University of Kansas Medical Center Cancer Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated:  3/21/2018
Red Cedar Wellness Center
mi
from
Bellevue, WA
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated: 3/21/2018
Red Cedar Wellness Center
mi
from
Bellevue, WA
Click here to add this to my saved trials
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated:  3/21/2018
Seattle Integrative Oncology at Providence Integrative Cancer Care
mi
from
Lacey, WA
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated: 3/21/2018
Seattle Integrative Oncology at Providence Integrative Cancer Care
mi
from
Lacey, WA
Click here to add this to my saved trials
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated:  3/21/2018
Seattle Cancer Treatment & Wellness Center
mi
from
Renton, WA
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated: 3/21/2018
Seattle Cancer Treatment & Wellness Center
mi
from
Renton, WA
Click here to add this to my saved trials
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated:  3/21/2018
Seattle Integrative Oncology at Institute of Complementary Medicine
mi
from
Seattle, WA
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated: 3/21/2018
Seattle Integrative Oncology at Institute of Complementary Medicine
mi
from
Seattle, WA
Click here to add this to my saved trials
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated:  3/21/2018
Tree of Health Integrative Medicine
mi
from
Woodinville, WA
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated: 3/21/2018
Tree of Health Integrative Medicine
mi
from
Woodinville, WA
Click here to add this to my saved trials
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated:  3/21/2018
Bastyr Integrative Oncology Research Center
mi
from
Kenmore, WA
Integrative Oncology Outcomes Study in Breast Cancer
Breast Cancer Integrative Oncology: Prospective Matched Controlled Outcomes Study
Status: Enrolling
Updated: 3/21/2018
Bastyr Integrative Oncology Research Center
mi
from
Kenmore, WA
Click here to add this to my saved trials
Second Echelon Node Study With Methylene Blue
Feasibility of Lymphatic Mapping of Second Echelon Lymph Nodes With Methylene Blue
Status: Enrolling
Updated:  3/21/2018
Mayo Clinic Rochester
mi
from
Rochester, MN
Second Echelon Node Study With Methylene Blue
Feasibility of Lymphatic Mapping of Second Echelon Lymph Nodes With Methylene Blue
Status: Enrolling
Updated: 3/21/2018
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Kinetics of Troponin and BNP in Breast Cancer Chemotherapy With Adriamycin and Trastuzumab
Pilot Study of the Kinetics of High Sensitivity Troponin and Brain Natriuretic Peptide in Breast Cancer Chemotherapy With Adriamycin and Trastuzumab
Status: Enrolling
Updated:  3/21/2018
Mayo Clinic
mi
from
Jacksonville, FL
Kinetics of Troponin and BNP in Breast Cancer Chemotherapy With Adriamycin and Trastuzumab
Pilot Study of the Kinetics of High Sensitivity Troponin and Brain Natriuretic Peptide in Breast Cancer Chemotherapy With Adriamycin and Trastuzumab
Status: Enrolling
Updated: 3/21/2018
Mayo Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
ATTN-Research Pharmacist
mi
from
Aurora, CO
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
ATTN-Research Pharmacist
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
University of Colorado Cancer Center
mi
from
Aurora, CO
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
University of Colorado Hospital - Anschutz Outpatient Pavilion
mi
from
Aurora, CO
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
University of Colorado Hospital - Anschutz Outpatient Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
Connecticut Multispecialty Group
mi
from
Enfield, CT
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
Connecticut Multispecialty Group
mi
from
Enfield, CT
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
Florida Cancer Specialists
mi
from
Sarasota, FL
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
Florida Cancer Specialists
mi
from
Sarasota, FL
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
The West Clinic
mi
from
Corinth, MS
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
The West Clinic
mi
from
Corinth, MS
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
The West Clinic, PC
mi
from
Southaven, MS
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
The West Clinic, PC
mi
from
Southaven, MS
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
Memorial Sloan Kettering Cancer Center - IDS Pharmacy
mi
from
New York, NY
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
Memorial Sloan Kettering Cancer Center - IDS Pharmacy
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
Memorial Sloan Kettering Cancer Center - OPD Pharmacy
mi
from
New York, NY
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
Memorial Sloan Kettering Cancer Center - OPD Pharmacy
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
The West Clinic, PC
mi
from
Memphis, TN
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
Sarah Cannon Research Institute
mi
from
Nashville, TN
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated:  3/22/2018
West Clinic
mi
from
Germantown, TN
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
A Phase 1 Open-label, Dose Escalation Study Evaluating The Safety, Tolerability, And Pharmacokinetics Of Enzalutamide (Formerly Mdv3100) In Patients With Incurable Breast Cancer
Status: Enrolling
Updated: 3/22/2018
West Clinic
mi
from
Germantown, TN
Click here to add this to my saved trials
Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
A Phase II Study of Irinotecan and Temozolomide in Breast Cancer Patients With Brian Metastases That Have Progressed After Stereotactic Radiosurgery or Whole Brain Radiation
Status: Enrolling
Updated:  3/23/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases
A Phase II Study of Irinotecan and Temozolomide in Breast Cancer Patients With Brian Metastases That Have Progressed After Stereotactic Radiosurgery or Whole Brain Radiation
Status: Enrolling
Updated: 3/23/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Fasting on Newly Diagnosed Breast Cancer
A Pilot Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer (STEFNE Study)
Status: Enrolling
Updated:  3/26/2018
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Fasting on Newly Diagnosed Breast Cancer
A Pilot Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer (STEFNE Study)
Status: Enrolling
Updated: 3/26/2018
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients
Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients Undergoing Embryo or Oocyte Cryopreservation: A Prospective Controlled Follow up Study
Status: Enrolling
Updated:  3/27/2018
IFPn
mi
from
Valhalla, NY
Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients
Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients Undergoing Embryo or Oocyte Cryopreservation: A Prospective Controlled Follow up Study
Status: Enrolling
Updated: 3/27/2018
IFPn
mi
from
Valhalla, NY
Click here to add this to my saved trials
Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer
Presurgical Phase IIB Trial of Oral CDB-4124 vs. Placebo in Women With Stage I-II Primary Breast Cancer
Status: Enrolling
Updated:  3/27/2018
Northwestern University
mi
from
Chicago, IL
Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer
Presurgical Phase IIB Trial of Oral CDB-4124 vs. Placebo in Women With Stage I-II Primary Breast Cancer
Status: Enrolling
Updated: 3/27/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  3/27/2018
Jefferson Clinic
mi
from
Birmingham, AL
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 3/27/2018
Jefferson Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  3/27/2018
UAB Comprehensive Cancer Center-LNB 301
mi
from
Birmingham, AL
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 3/27/2018
UAB Comprehensive Cancer Center-LNB 301
mi
from
Birmingham, AL
Click here to add this to my saved trials
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  3/27/2018
Providence Alaska Medical Center
mi
from
Anchorage, AK
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 3/27/2018
Providence Alaska Medical Center
mi
from
Anchorage, AK
Click here to add this to my saved trials
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  3/27/2018
The University of California, San Diego
mi
from
La Jolla, CA
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 3/27/2018
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  3/27/2018
University of California-Davis
mi
from
Sacramento, CA
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 3/27/2018
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  3/27/2018
Los Angeles Biomedical Research Institute
mi
from
Torrance, CA
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 3/27/2018
Los Angeles Biomedical Research Institute
mi
from
Torrance, CA
Click here to add this to my saved trials
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  3/27/2018
University of Connecticut Health Center
mi
from
Farmington, CT
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 3/27/2018
University of Connecticut Health Center
mi
from
Farmington, CT
Click here to add this to my saved trials
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  3/27/2018
The Whittingham Cancer Center, Norwalk Hospital
mi
from
Norwalk, CT
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 3/27/2018
The Whittingham Cancer Center, Norwalk Hospital
mi
from
Norwalk, CT
Click here to add this to my saved trials
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  3/27/2018
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 3/27/2018
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  3/27/2018
University of Miami School of Medicine
mi
from
Miami, FL
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 3/27/2018
University of Miami School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  3/27/2018
Georgia Cancer Specialists
mi
from
Tucker, GA
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 3/27/2018
Georgia Cancer Specialists
mi
from
Tucker, GA
Click here to add this to my saved trials
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  3/27/2018
John H. Stroger, Jr. Hospital of Cook County
mi
from
Chicago, IL
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 3/27/2018
John H. Stroger, Jr. Hospital of Cook County
mi
from
Chicago, IL
Click here to add this to my saved trials
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  3/27/2018
Mercy Hospital and Medical Center
mi
from
Chicago, IL
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 3/27/2018
Mercy Hospital and Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  3/27/2018
University of Chicago Medical Center
mi
from
Chicago, IL
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 3/27/2018
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  3/27/2018
Loyola University Medical Centre
mi
from
Maywood, IL
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 3/27/2018
Loyola University Medical Centre
mi
from
Maywood, IL
Click here to add this to my saved trials
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  3/27/2018
Trinity Medical Center
mi
from
Moline, IL
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 3/27/2018
Trinity Medical Center
mi
from
Moline, IL
Click here to add this to my saved trials
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  3/27/2018
Mid-Illinois Hematology & Oncology Associates, Ltd
mi
from
Normal, IL
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 3/27/2018
Mid-Illinois Hematology & Oncology Associates, Ltd
mi
from
Normal, IL
Click here to add this to my saved trials
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  3/27/2018
Carle Cancer Centre
mi
from
Urbana, IL
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 3/27/2018
Carle Cancer Centre
mi
from
Urbana, IL
Click here to add this to my saved trials
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated:  3/27/2018
Indiana University Medical Center
mi
from
Indianapolis, IN
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Status: Enrolling
Updated: 3/27/2018
Indiana University Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials